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models.  
Objectives: Investigate the analgesic effect of lithium on the cuff model of 
neuropathic pain.  
Methods: We used behavioral and pharmacological approaches to study the 
analgesic effect of a single injection of lithium in wild-type and mu opioid 
receptor (MOR) null cuffed neuropathic mice. Mass spectrometry and ELISA 
allowed to measure the levels of endogenous MOR agonist beta-endorphin, 
as well as monoamines in brain and plasma samples 4 hours after lithium 
administration.  
Results: A single injection of lithium chloride (100mg/kg, ip) alleviated 
mechanical allodynia for 24 hours and this effect was absent in MOR null 
neuropathic mice. Biochemical analyses highlight a significant increase of 
beta-endorphin levels by 30% in the brain of lithium-treated mice 
compared to controls. No variation of beta-endorphin was detected in the 
blood.  
Conclusions: Together, our results provide evidence that lithium induces a 
long-lasting analgesia in neuropathic mice presumably through elevated 
brain levels of beta-endorphin and the activation of MORs. 
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Abstract 
Background: Lithium is widely used to treat bipolar disorders and displays mood 
stabilizing properties. In addition, lithium relieves painful cluster headaches and has a 
strong analgesic effect in neuropathic pain rat models. 
Objectives: Investigate the analgesic effect of lithium on the cuff model of neuropathic 
pain.  
Methods: We used behavioral and pharmacological approaches to study the analgesic 
effect of a single injection of lithium in wild-type and mu opioid receptor (MOR) null 
cuffed neuropathic mice. Mass spectrometry and ELISA allowed to measure the levels of 
endogenous MOR agonist beta-endorphin, as well as monoamines in brain and plasma 
samples 4 hours after lithium administration. 
Results: A single injection of lithium chloride (100mg/kg, ip) alleviated mechanical 
allodynia for 24 hours and this effect was absent in MOR null neuropathic mice. 
Biochemical analyses highlight a significant increase of beta-endorphin levels by 30% in 
the brain of lithium-treated mice compared to controls. No variation of beta-endorphin was 
detected in the blood.  
Conclusions: Together, our results provide evidence that lithium induces a long-lasting 
analgesia in neuropathic mice presumably through elevated brain levels of beta-endorphin 
and the activation of MORs. 
 
Keywords 
Lithium, neuropathy, analgesia, mu opioid receptor, beta-endorphin, monoamines. 
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 3 
Background 
Lithium is a metallic ion displaying chaotropic and denaturating properties (Breslow and 
Guo, 1990). This metal is described to treat bipolar disorders (Chiu and Chuang, 2010), to 
be able to reduce painful cluster headache (Leone et al., 2010) and to decrease 
inflammation (Nassar and Azab, 2014). Several research groups reported functional 
interactions between lithium and the opioid system. In particular, lithium affects morphine-
induced analgesia (Johnston and Westbrook, 2004; Dehpour et al., 1994), and reduces 
morphine tolerance and dependence (Dehpour et al., 1995; Alborzi et al., 2006). Lithium 
attenuates thermal hyperalgesia and mechanical allodynia in different models of 
neuropathic pain in rats via a naloxone-sensitive mechanism, suggesting that lithium action 
is opioid receptor-dependent (Banafshe et al., 2012; Shimizu et al., 2000). In addition, 
lithium prevents paclitaxel-induced peripheral neuropathy (Mo et al., 2012), increases 
survival by allowing the use of higher doses of paclitaxel and prevents paclitaxel-induced 
cardiac abnormalities. 
The present study reveals that a single injection of lithium alleviates neuropathic pain 
symptoms in a mouse model of sciatic nerve chronic constriction and demonstrates for the 
first time MOR involvement in lithium analgesia. In this context the potential variations of 
endogenous opioid, as well as monoamine levels have been studied after lithium injection. 
 
Methods 
Animals 
Experiments were performed with 45 day-old adult male C57BL/6J mice (25±4 g; 
Charles River, L’Arbresle, France). Mu opioid receptor (MOR) null mice were a 
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 4 
generous gift from Pr. B. Kieffer (IGBMC, Illkirch-Graffenstaden, France). Animals 
were given free access to food and water, with a 12 h light–dark cycle at a temperature 
of 22°C±2°C. All procedures were performed in accordance with European directives 
(2010/63/EU) and were approved by the regional ethics committee and the French 
Ministry of Agriculture (license No. 00456.02 to Y.G.). The right sciatic nerve was 
cuffed with a section of polyethylene tubing (cuff group) as previously described 
(Benbouzid et al., 2008). Briefly, surgeries were done under aseptic conditions and 
ketamine/xylazine was used for anesthesia (ketamine: 17 mg/mL, i.p., xylazine: 2.5 
mg/mL, i.p., 4 mL/kg; Centravet, Taden, France). After a performing a 1.5 cm skin 
incision of the right hind thigh, a 2 mm long polyethylene tubing was placed on the 
common branch of the right sciatic nerve (ID = 0.38 mm, ED = 1.09 mm; PE-20, 
Harvard Apparatus, Les Ulis, France) and sutures were used to close the skin 
(Benbouzid et al., 2008). Sham-operated mice underwent the same surgical procedure as 
cuffed animals without implantation of the cuff. 
 
Response to mechanical stimuli 
The mechanical threshold for hind paw withdrawal was determined using Von Frey hairs 
as previously described (Benbouzid et al., 2008). Intraperitoneal injections of a solution of 
100mg/kg of lithium chloride (corresponding to 16.4 mg/ml of lithium; Sigma-Aldrich, St. 
Louis, U.S.A.) diluted in NaCl 0.9% (w/v; saline), naloxone (Sigma-Aldrich) diluted in 
saline or an equivalent volume of saline were performed at 10 am. Injections of naloxone 
(0.1 mg/kg, s.c.) were performed 4 h after the injections of lithium (corresponding to the 
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 5 
peak of analgesia observed for neuropathic mice) (Desmeules et al., 1993). Hind paw 
withdrawal was determined 15 min later. 
 
Response to thermal stimuli 
Mice were placed during 15 min in clear Plexiglas boxes (7 cm x 9 cm·x 7 cm) on a 
glass surface (Hargreaves et al., 1988). The infrared beam of the radiant heat source 
(7370 Plantar Test, Ugo Basile, Comerio, Italy) was applied to the plantar surface of 
each hindpaw. The cut-off to prevent damage to the skin was set at 15 s. The paw 
withdrawal latency was tested 3 times 4 h after lithium injection and was averaged for 
each hindpaw. 
 
Sample preparation  
Plasma was prepared from blood recovered in tubes containing 50 µl of 2% EDTA (w/v) 
and protease inhibitors (cOmplete Mini EDTA-free, Roche, Basel, Switzerland). 
Brain was homogenized in 2 ml of 0.5 µM ascorbic acid containing protease inhibitors 
and sonicated for 10 s at 90 W and centrifuged (20,000 g, 15 min, 4°C). Supernatant was 
recovered and protein content was determined using the Protein Assay kit (Bio-Rad, 
Marnes-la-Coquette, France). 
 
Monoamines and catecholamines derivatization 
The presence of L-DOPA; dopamine, adrenaline; noradrenaline, serotonin and adenosine 
was studied. 20 µl of tissue extracts or plasma were derived with the AccQ-Tag Ultra 
Derivatization kit (Waters, Guyancourt, France). 20 µl of the sample were added to 30 µl 
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 6 
of borate buffer (provided within the kit) and 10 µl of internal standards ([
2
H3]-L-DOPA, 
[
2
H4]-dopamine, [
2
H6]-adrenaline, [
13
C6]-noradrenaline, [
2
H4]-serotonin, [
13
C5]-adenosine; 
Sigma Aldrich and Alsachim, Illkirch, France). Derivatization was performed by addition 
of 10 µl of AccQtag Ultra reagent (10 min, 55°C under agitation). 10 µl of this solution 
were analyzed using a LC-MS/MS approach. 
 
Beta-endorphin ELISA 
Beta-endorphin concentrations in the brain and plasma were quantified using a direct 
ELISA (M0184 ELISA, Clinisciences-Elabscience, Nanterre, France) according to the 
manufacturer's instruction. Samples (50 µl) were analyzed in duplicate. All samples with a 
duplicate CV>5% were retested to obtain a CV below or equal to 5%. Detection Range 
was 15.63-1000 pg/ml and sensitivity was 9.38 pg/ml of beta-endorphin. 
 
LC-MS/MS instrumentation and analytical conditions 
Analyses were performed with a Dionex Ultimate 3000 HPLC system (Thermo 
Scientific, San Jose, USA) coupled with a triple quadrupole Endura. The system was 
controlled by Xcalibur v2.0 software. Samples were loaded onto an Accucore RP-MS 
column (100x2.1 mm, 2 µm, Thermo Electron) heated at 50°C. Buffer A was H2O 
99.9%/formic acid 0.1% (v/v), whereas buffer B was ACN 99.9%/formic acid 0.1% (v/v). 
Gradients used are detailed in Table 1. 
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 7 
Table 1- LC and MS conditions for the purification and the detection of catecholamines 
and monoamines and their respective heavy tagged counterparts. Buffer A corresponded to 
ACN 1% / H2O 98.9% / formic acid 0.1% (v/v/v), whereas buffer B was ACN 99.9 % / 
formic acid 0.1% (v/v).  
 
Electrospray ionization was achieved in the positive mode with the spray voltage set at 
3,750 V. Nitrogen was used as the nebulizer gas and the ionization source was heated to 
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 8 
250°C. Desolvation (nitrogen) sheath gas was set to 45 Arb and Aux gas was set to 15 Arb. 
Ion transfer tube was heated at 350°C. Q1 and Q2 resolutions were set at 0.7 FWHM, 
whereas collision gas (CID, argon) was set to 2 mTorr. Identification of the compounds 
was based on precursor ion, selective fragment ions and retention times. Selection of the 
monitored transitions and optimization of collision energy and RF Lens parameters were 
manually determined (see Table 1 for details). Qualification and quantification were 
performed in MRM mode using Quan Browser software (Thermo Scientific). Limits of 
detection (LOD) and of quantification for each compound are indicated in Table 2. All 
amounts of opiates present in samples fit within the standard curve limits, Precision values 
were <1% for same-day measurements and <5% for inter-day measurements.  
  Adenosine Adrenaline Dopamine L-DOPA Noradrenaline Serotonin 
LOD  
(fmol ± SEM) 
9,77 ± 1,20 0,71 ± 0,29 4,64 ± 1,54 43,31 ± 1,04 3,39 ± 0,74 
24,04 ± 
0,22 
LOQ 
(fmol ± SEM) 
32,53 ± 3,99 2,36 ± 0,97 
15,46 ± 
5,14 
144,24 ± 
3,45 
11,29 ± 2,45 
80,05 ± 
0,73 
 
Table 2- Limits of detection (LOD), limits of quantification (LOQ) for all compounds. 
LOD was defined as the lowest detectable amount of analyte with a signal-to-noise (S/N) 
ratio >3. LOQ was defined as the lowest detectable amount of analyte with a signal-to-
noise (S/N) ratio >10. Data are presented as the mean ± SEM of 5 measurements. 
 
Statistics 
Statistical analysis was performed using GraphPad Prism 6 Software. Results were 
presented as mean values ± standard error of the mean (SEM). Groups were compared 
using ANOVA tests with Bonferroni correction.  
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 9 
RESULTS 
Effect of lithium on the mechanical nociceptive threshold in the cuff neuropathic 
pain model 
Cuff and Sham mice were tested for mechanical pain threshold using the Von Frey 
filaments test. The cuff group showed a significant mechanical allodynia compared to the 
sham group (Fig. 1A). Lithium injection performed six days after surgery did not affect the 
mechanical pain threshold of the sham group. Conversely, in the neuropathic cuff group, 
lithium normalized the ipsilateral mechanical pain threshold to sham group values. This 
analgesic effect of a single injection lasted for about 24 h (Fig. 1A). The contralateral paw 
mechanical pain threshold was unaffected (Fig. 1B) and no statistical difference before and 
after lithium injection was observed. Additional experiments were designed to determine 
the effect of lithium 4 h after administration on thermal hyperalgesia (6 days after the 
surgery). The Hargreaves test (Fig. 1C) shows a significant relief of thermal hyperalgesia 
for the ipsilateral paw compared to the pretest condition (before lithium administration; 
n=6; Mann–Whitney U test; p<0.01). Heat-nociceptive threshold of the contralateral paw 
was not affected by lithium, 
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 10 
  
Fig. 1- Analgesic effect of lithium chloride. Antinociceptive effect of lithium chloride 
(100 mg/kg, i.p., day 6) vs vehicle (NaCl) on sham and cuffed mice. A, Effect of lithium 
administration on ipsilateral paw mechanical allodynia. B, contralateral paw. n=6; Two 
way ANOVA test with a Bonferroni correction. ** , p<0.01). C, effect of lithium 4 h after 
administration on thermal hyperalgesia (6 days after the surgery; Hargreaves test); n=6; 
Mann–Whitney U test; **, p<0.01). Values are means ± SEM. 
 
Effect of naloxone on lithium-induced analgesia 
In order to determine if this analgesic effect involves the endogenous opioid system, 
naloxone (0.1 mg/kg, s.c.), a non-specific opioid receptor antagonist, was administered 4 h 
after lithium injections (corresponding to the peak of analgesia observed for neuropathic 
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 11 
mice; Fig.1A). Naloxone alone did not modify the mechanical threshold, but significantly 
decreased the analgesic effect of lithium compared to pre-test values (Fig. 2A) when 
testing the ipsilateral paw. The contralateral paw mechanical pain threshold was not 
affected. 
    
Fig. 2- Mu opioid receptor-dependent analgesic effect of lithium chloride on 
neuropathic mice. A, Effect of naloxone (0.1 mg/kg, s.c..) on lithium-induced analgesia 
(100 mg/kg, i.p.). n=6 per group; two way ANOVA test with a Bonferroni correction; 
$=p<0.01. B, Effect of lithium chloride on MOR null neuropathic mice; n=6 per group, 
ANOVA test ; n=6; ns, non significant. Values are means ± SEM. Pretesting group 
corresponds to mechanical threshold before lithium and/or naloxone injections. 4h group 
corresponds to mechanical threshold observed 4h after lithium and/or naloxone injections. 
 
Effect of lithium on neuropathic MOR-null mice 
To assess whether MORs were necessary to observe lithium analgesia, sham and cuff 
MOR null mice were treated with a single injection of lithium. Lithium-induced analgesia 
was never observed in MOR-null mice (Fig. 2B) as illustrated by the stability of the mean 
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 12 
mechanical threshold observed in lithium and vehicle-treated cuffed mice. No effect was 
observed on the contralateral paw mechanical pain threshold. 
 
Effect of lithium on the level of endogenous mediators 
While MORs have been long known to promote analgesia, opioid ligands such as beta-
endorphin as well as non opioid neurotransmitters may be produced locally or after 
recruitment of classical pain controls acting in CNS circuits or at the periphery. Plasma and 
brains of saline and lithium-treated neuropathic animals were analyzed using biochemical 
approaches aimed at measuring plasma levels of noradrenaline, adenosine, serotonin and 
beta-endorphin. No differences between saline- and lithium-treated cuff groups were found 
(Fig. 3). Adrenaline, dopamine and L-Dopa were below detection levels. Values obtained 
for beta-endorphin, serotonin, noradrenaline and adenosine were in agreement with values 
published in the literature (Fell et al., 2014; Grouzmann et al., 2003; Ziu et al., 2014; Hu et 
al., 2016). 
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 13 
 
Fig. 3- Effect of lithium chloride on noradrenaline, adenosine, serotonin and beta-
endorphin plasma levels of neuropathic mice. Li, Lithium chloride; n=7 or 8. Mann-
Whitney test. 
 
In the brain, adrenaline, noradrenaline, dopamine, L-Dopa, adenosine and serotonin 
levels were not affected by a lithium treatment (Fig. 4) and were in agreement with levels 
described for healthy animals (Gogos et al., 1998; Delaney et al., 1998; Bengel et al., 
1998). In sharp contrast, beta-endorphin levels were significantly increased by 30% 
(p=0.0047; 54.9±4.1 pg/mg of brain protein) in lithium-treated cuff mice compared to the 
saline group (42.1±2.1 pg/mg). Similarly, the values of beta-endorphin brain levels (low 
pg/mg physiological range) are consistent with previous studies (Gong et al., 2014). 
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 14 
 
Fig. 4- Effect of lithium chloride on adrenaline, noradrenaline, dopamine, L-Dopa, 
adenosine, serotonin and beta-endorphin brain levels of cuffed mice. Li, Lithium 
chloride; n=8, 7 or 6 (please see graphs). Mann-Whitney test.; *, p<0.05; **, p<0.01. 
Values are means ± SEM. 
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 15 
In addition to the physiological processing of acute pain by the nociceptive system, 
inflammatory and neuropathic insults may sometimes result in chronic pain that persists 
long after recovery from the initial lesions (taxonomy., 1986). In such pathological states, 
pain no longer plays its physiological warning role. Most therapeutic approaches aimed at 
alleviating chronic pain symptoms have beneficial effects but suffer from adverse side 
effects (Dworkin et al., 2010; Ho and Siau, 2009). This is the case for morphine and related 
opiates that are widely prescribed to chronic pain patients and may lead to the development 
of tolerance, opioid-induced hyperalgesia and addiction (Roeckel et al., 2016; Williams et 
al., 2013). Therefore, alternative therapeutic strategies are needed. 
Studies examining the role of lithium on pain responses are unfortunately contradictory 
so far. On one side, lithium seems to induce hyperalgesia and to decrease morphine-
induced analgesia (Wiertelak et al., 1994; McNally and Westbrook, 1998; Johnston and 
Westbrook, 2004). In addition, lithium overdose can, in a few cases, cause peripheral 
neuropathy or myopathy in patients (Timmer and Sands, 1999). In mice and rats, it has 
been hypothesized that lithium induces a biphasic effect on morphine-induced analgesia 
that is dependent on lithium concentration and on the pain test used (de Gandarias et al., 
2000; Dehpour et al., 1994; Raffa and Martinez, 1992). On the other hand, several groups 
did not observe any direct effect of lithium on pain perception using a mouse model 
(Karakucuk et al., 2006). 
Interestingly, lithium was shown to relieve cluster headache, which causes pain episodes 
of extreme intensity. Lithium also reduced the associated autonomic symptoms in humans 
(Robbins et al., 2016). Moreover, acute and chronic administration of lithium induce a 
direct analgesia in neuropathic pain states (Mannisto and Saarnivaara, 1972; Banafshe et 
Page 16 of 26
https://mc.manuscriptcentral.com/molecularpain
Molecular Pain
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
 16 
al., 2012; Shimizu et al., 2000; ), and potentiate morphine analgesia in mouse and rat 
models (Karakucuk et al., 2006; Jensen, 1974). Lithium treatments also reversed thermal 
hyperalgesia, as well as the mechanical and cold allodynia induced by a partial sciatic 
nerve ligation in rats in a naloxone-sensitive manner (Banafshe et al., 2012; Shimizu et al., 
2000; ). Furthermore, lithium has been shown to prevent paclitaxel-induced peripheral 
neuropathy in mice (Mo et al., 2012). In humans, a clinical trial performed with lithium 
medication had a favorable effect on sciatic nerve injury (SNI) neuropathic pain (Yang et 
al., 2012); moreover, lithium was able to relieve tricyclic antidepressants-refractory 
fibromyalgia (Tyber, 1990). Our present data confirm the long-lasting analgesic effect of 
acute lithium administration on a well characterized mouse neuropathic model(Benbouzid 
et al., 2008). In addition, we show that MORs are necessary for lithium-induced analgesia, 
as no analgesic effect was observed in MOR-null mice. 
Lithium acts on numerous targets that have been recently reviewed (Alda, 2015; Oruch et 
al., 2014). Different mechanisms of action have been proposed and include a possible 
substitution of Na
+
 by Li
+
 impacting homeostasis of electrolyte balance and therefore 
neuronal firing, or a modulation of the membrane transport of different ions and 
neurotransmitter precursors (Jope et al., 1978). In rats, lithium aversive effects (place-
preference conditioning procedure) were abolished by naloxone, suggesting a beta-
endorphin-dependent mechanism (Shippenberg et al., 1988). In addition to being a 
modulator of NO production in the brain, lithium inhibits Gi and Gs proteins leading to an 
inhibition of adenylate and guanylate cyclases and of different protein kinases (Schubert et 
al., 1991). Moreover, lithium affects GSK-3β (glycogen synthase kinase 3 (Klein and 
Melton, 1996)) acting therefore on both Akt (protein kinase B) and Wingless-related 
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integration site (Wnt) signaling (Valvezan and Klein, 2012). This compound is also able to 
inhibit inositol monophosphatase and inositol polyphosphate-1-phosphatase (Lopez-
Coronado et al., 1999; Shaltiel et al., 2009), influencing inositol-dependent regulatory 
processes. It also reduces CREB phosphorylation and decreases CREB-dependent gene 
expression (Boer et al., 2008). Lithium’s anti-inflammatory properties lead to a down-
regulation of both proinflammatory cytokines and TNF-alpha interleukin and intracellular 
mechanisms including GSK-3β (Nassar and Azab, 2014). Finally, lithium has also been 
shown to regulate the biosynthesis of different neurotransmitters and/or associated 
receptors (e.g., modulation of serotonin and glutamate synthesis and secretion) (Lenox and 
Wang, 2003; Massot et al., 1999; Scheuch et al., 2010; Jope, 1999; Shippenberg et al., 
1988). 
Our results indicate that acute lithium treatment has a strong anti-allodynic effect as well as 
a stimulatory effect (+30%) on the production of brain beta-endorphin, a MOR agonist 
displaying strong analgesic properties. In good agreement with our data, it has been 
described that stress-induced analgesia is absent in mice lacking beta-endorphin (Rubinstein 
et al., 1996) and that ultraviolet light induces both analgesia and addiction through a 35% 
increase of plasma beta-endorphin levels (Fell et al., 2014). More recently, 
photobiomodulation therapy performed on the chronic constriction injury mouse model 
(CCI) correlated the level of pain relief to an increase of beta-endorphin levels (de Andrade 
et al., 2017). However this effect is still unclear since previous studies reported that in vivo 
chronic treatment with lithium did not modify beta-endorphin levels in different rat brain 
structures (Shippenberg and Herz, 1991) whereas in vitro and ex vivo experiments 
demonstrated that an acute stimulation with lithium increases the release of hypothalamic 
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beta-endorphin (Burns et al., 1990). As a 35% blood beta-endorphin increase induces a 
strong elevation of mechanical and thermal thresholds (Fell et al., 2014), the 30% increase in 
beta-endorphin brain content we observed after lithium injection should likely be sufficient 
to induce a robust analgesia.  
Plasma levels of beta-endorphin are tightly linked to secretions from the pituitary and 
adrenal gland, whereas brain and cerebrospinal fluid levels are mainly dependent on the 
arcuate nucleus of the hypothalamus and of the brainstem nucleus tractus solitaris. In 
addition, beta-endorphin displays a short half-life in rodents’ blood (2 to 10 min) (Houghten 
et al., 1980; Silman et al., 1977) while in the CNS, degradation of beta-endorphin is 
described to be extremely long (Burbach et al., 1979; Silman et al., 1977).  
Therefore, the beta-endorphin elevation observed in the brain 4 h after a lithium injection 
is likely due to (i) an up-regulation of beta-endorphin production from the arcuate nucleus 
and the nucleus tractus solitaris associated with a (ii) longer brain half-life. While the cuff is 
a model of peripheral neuropathy, CNS beta-endorphin secretion can normalize the 
ipsilateral paw threshold by acting on supraspinal (e.g. periaqueductal gray, rostral 
ventromedial medulla) or spinal nociceptors.  
Together with other studies showing the analgesic effect of acute lithium treatment on 
chronic pain, our results suggest that lithium analgesia involves the upregulation of beta-
endorphin synthesis in the CNS. This would explain, at least in part, the MOR-dependent 
nature of the analgesic properties of lithium. 
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